MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2215/cjn.03000311

Медицинская библиотека · Clinical journal of the American Society of Nephrology : CJASN · 2012

Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.

Cheng Jun, Zhang Wen, Zhang Xiaohui, Li Xiayu, Chen Jianghua

СтатьяМетаанализОбзорПеревод пока не подготовлен

Аннотация

BACKGROUND AND

OBJECTIVES

Observational data indicate that newer vitamin D compounds such as paricalcitol can suppress serum intact parathyroid hormone (iPTH) and reduce proteinuria in patients with CKD. To systematically evaluate the efficacy and safety of paricalcitol for CKD, we conducted a meta-analysis of the published randomized controlled trials (RCTs).

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: MEDLINE, Embase, the Cochrane Library, and article reference lists were searched for RCTs that compared paricalcitol with placebo in the treatment of patients with stage 2-5 CKD. The quality of the studies was evaluated using the Jadad method. The results are summarized as risk ratios (RRs) for dichotomous outcomes or mean differences for continuous outcomes.

RESULTS

Nine studies (832 patients) were included. Compared with placebo, paricalcitol suppressed serum iPTH (RR, 6.37; 95% confidence interval [95% CI], 4.64-8.74; P<0.001) and reduced proteinuria (RR, 1.68; 95% CI, 1.25-2.25; P<0.001). Compared with the control group, the RR for hypercalcemia associated with paricalcitol use was 2.25 (95% CI, 0.81-6.26; P=0.12). Patients receiving paricalcitol therapy did not have an increased risk of endocrine system and cardiovascular system adverse effects (RR, 1.07; 95% CI, 0.84-1.36; P=0.58).

CONCLUSIONS

We confirm that paricalcitol suppresses iPTH and lowers proteinuria in patients with stage 2-5 CKD without an increased risk of adverse events. A trend toward increased hypercalcemia did not reach statistical significance, but may be clinically relevant. A randomized trial is needed to determine if paricalcitol affects the development of ESRD or mortality.

Для цитирования: Cheng Jun, Zhang Wen, Zhang Xiaohui, Li Xiayu, Chen Jianghua. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.. Clinical journal of the American Society of Nephrology : CJASN. 2012. DOI: 10.2215/cjn.03000311.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.